

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ocumension Therapeutics**  
**歐康維視生物**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 1477)**

## **PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE SEVENTH MEMORANDUM AND ARTICLES OF ASSOCIATION**

This announcement is made by Ocumension Therapeutics (the “**Company**”) pursuant to Rule 13.51(1) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors of the Company proposes to amend the existing memorandum and articles of association of the Company (the “**Existing M&A**”) and to adopt the seventh amended and restated memorandum and articles of association (the “**New M&A**”) in substitution for, and to the exclusion of, the Existing M&A in order to, further optimize the implementation of (i) the expansion of paperless listing regime and electronic dissemination of corporate communications as stated in the conclusions published by the Stock Exchange to its consultations on the “Proposals to Expand Paperless Listing Regime and Other Rule Amendments” and “Proposals to Further Expand the Paperless Listing Regime and Other Rule Amendments”; and (ii) the new treasury shares regime as stated in the conclusions published by the Stock Exchange to its consultation on the “Proposed Amendments to Listing Rules Relating to Treasury Shares”.

The proposed amendments to the Existing M&A and adoption of the New M&A are subject to the approval of the shareholders of the Company (the “**Shareholders**”) by way of a special resolution at the forthcoming annual general meeting (the “**AGM**”) of the Company, and will become effective upon the approval by the Shareholders at the AGM. A circular containing, among other things, further details concerning the proposed amendments to the Existing M&A and the full terms of the proposed amendments, together with the notice of the AGM and the proxy form, will be despatched to the Shareholders in due course.

By order of the Board  
**Ocumension Therapeutics**  
**Dr. Lian Yong CHEN**  
*Chairman and Non-executive Director*

Hong Kong, March 31, 2025

*As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.*